EUCTR2005-005967-27-IT进行中（未招募）不适用
Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmacodynamics - PROMET
AZIENDA USL 6 LIVORNO ZONA LIVORNESE0 个研究点目标入组 27 人开始时间: 2006年2月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Patients with diagnosis of ormonorefrattario prostatico carcinoma in advanced phase - ECOG PS 2 - Attended of life at least 3 months - Adapted renal functionality creatinina 1,25 x V.N. - Adapted hepatic functionality bilirubina tot. 1,5 x V.N., SGOT and SGPT 3 xV.N., - Adapted reservoir medullary GB 3000/mcl, PLT 100.000/mcl, Hgb 10 g/dl. - informed Consent written - Suspension from at least 30 drug days antiandrogens with demonstration not answer of the PSA to the suspension
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Scompensate metabolic diseases or serious infections in action - cardiac Arrhythmies or ischemic cardiopathy and presence of whichever elevated cardiovascular risk - Impossibility to execute adequate follow-up - Presence of sintomatic encefalic metastases - a Presence of second neoplasia. - gastroduodenal Presence of ulcera
研究者
相似试验
进行中（未招募）
1 期
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
进行中（未招募）
1 期
Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumorEUCTR2021-002540-67-FRCentre Oscar Lambret28
招募中
不适用
A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancersadvance and recurrent gynecological cancerJPRN-UMIN000016438Saitama Medical University International Medical Center30
进行中（未招募）
不适用
A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2010-024266-21-ITISTITUTO EUROPEO DI ONCOLOGIA100
进行中（未招募）
不适用
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast canceradvanced or metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-006025-27-ITISTITUTO EUROPEO DI ONCOLOGIA